Javascript must be enabled to continue!
Glyburide inhibits the bone resorption induced by traumatic occlusion in rats
View through CrossRef
AbstractObjectiveTo examine whether glyburide inhibits bone destruction caused by traumatic occlusion in a rat occlusal trauma model.BackgroundExcessive mechanical stress, such as traumatic occlusion, induces expression of IL‐1β and may be involved in bone resorption. NLRP3 inflammasomes have been linked to IL‐1β expression, but it is currently unclear whether glyburide, the inhibiter of NLRP3 inflammasome, suppresses occlusal trauma in rats.MethodsMale SD rats aged 7 weeks were used. In the trauma group, the occlusal surface of the maxillary first right molar was raised by attaching a metal wire to apply occlusal trauma to the mandibular first right molar. In the trauma + glyburide group, the NLRP3 inhibitor glyburide was administered orally every 24 hours from 1 day before induction of occlusal trauma. Rats were euthanized after 5 or 10 days, and the maxillary first molars were harvested with the adjacent tissues for histopathological investigation. Immunohistochemical expression of IL‐1β, NLRP3, and RANKL was also assessed.ResultsOn day 5, bone resorption was significantly greater in the trauma group compared with the control group or the trauma + glyburide group, and there were significantly higher numbers of osteoclasts and cells positive for IL‐1β, NLRP3, and RANKL in the trauma group.ConclusionIn this study, glyburide inhibits bone resorption by traumatic occlusion in rats. It suggests that the NLRP3/IL‐1β pathway might be associated with bone resorption induced by traumatic occlusion.
Title: Glyburide inhibits the bone resorption induced by traumatic occlusion in rats
Description:
AbstractObjectiveTo examine whether glyburide inhibits bone destruction caused by traumatic occlusion in a rat occlusal trauma model.
BackgroundExcessive mechanical stress, such as traumatic occlusion, induces expression of IL‐1β and may be involved in bone resorption.
NLRP3 inflammasomes have been linked to IL‐1β expression, but it is currently unclear whether glyburide, the inhibiter of NLRP3 inflammasome, suppresses occlusal trauma in rats.
MethodsMale SD rats aged 7 weeks were used.
In the trauma group, the occlusal surface of the maxillary first right molar was raised by attaching a metal wire to apply occlusal trauma to the mandibular first right molar.
In the trauma + glyburide group, the NLRP3 inhibitor glyburide was administered orally every 24 hours from 1 day before induction of occlusal trauma.
Rats were euthanized after 5 or 10 days, and the maxillary first molars were harvested with the adjacent tissues for histopathological investigation.
Immunohistochemical expression of IL‐1β, NLRP3, and RANKL was also assessed.
ResultsOn day 5, bone resorption was significantly greater in the trauma group compared with the control group or the trauma + glyburide group, and there were significantly higher numbers of osteoclasts and cells positive for IL‐1β, NLRP3, and RANKL in the trauma group.
ConclusionIn this study, glyburide inhibits bone resorption by traumatic occlusion in rats.
It suggests that the NLRP3/IL‐1β pathway might be associated with bone resorption induced by traumatic occlusion.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Treatment of Type I Diabetes with a Combination of Glyburide and Insulin
Treatment of Type I Diabetes with a Combination of Glyburide and Insulin
OBJECTIVE:
To assess the ability of a combination of insulin and an oral hypoglycemic agent (glyburide) to improve the overall glycemic control in a population ...
Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis
Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis
Background:Leishmaniasis is caused by a protozoan parasite, Leishmania. It is common in more than 98 countries throughout the world. Due to insufficient availability of antileishma...
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Objectives:
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor superfamily that were first discovered by Marshall Urist. There are 14 B...
Biomechanical aspects of marginal bone resorption around osseointegrated implants: considerations based on a three‐dimensional finite element analysis
Biomechanical aspects of marginal bone resorption around osseointegrated implants: considerations based on a three‐dimensional finite element analysis
AbstractObjectives: Although bone loss around implants is reported as a complication when it progresses uncontrolled, resorption does not always lead to implant loss, but may be t...
Influence of marginal bone resorption on stress around an implant – a three‐dimensional finite element analysis
Influence of marginal bone resorption on stress around an implant – a three‐dimensional finite element analysis
summary Average marginal bone resorption of about 1 mm after the first year of functional loading, which is followed by an annual loss of approximately 0·1 mm, has been reported i...
Modulation by a Sulfonylurea of Insulin-dependent Glycogenesis, but Not of Insulin Binding, in Cultured Rat Hepatocytes: Evidence for a Postreceptor Mechanism of Action
Modulation by a Sulfonylurea of Insulin-dependent Glycogenesis, but Not of Insulin Binding, in Cultured Rat Hepatocytes: Evidence for a Postreceptor Mechanism of Action
To detect potential direct effects of the sulfonylurea glyburide on hepatic carbohydrate metabolism, we tested whether the drug was capable of modulating insulin binding and glycog...
Formulation Development and In vitro Evaluation of Combination Product of Glyburide and Metformin Hydrochloride Tablet
Formulation Development and In vitro Evaluation of Combination Product of Glyburide and Metformin Hydrochloride Tablet
This study was attempted to formulate a combination product of Glyburide and Metformin Hydrochloride Tablets USP 2.5mg/500mg and to evaluate their physico-chemical properties. Wet ...

